ArticleNature communications2021
Engineered reproductively isolated species drive reversible population replacement.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Identifying Target Genes for Engineered Genetic Incompatibility in Fish.Marine biotechnology (New York, N.Y.) · 2026Article
- Predicting thresholds for population replacement gene drives.BMC biology · 2024Article
- Manipulating the Destiny of Wild Populations Using CRISPR.Annual review of genetics · 2023Review
- CRISPR mediated transactivation in the human disease vector Aedes aegypti.PLoS pathogens · 2023Article
- Selective targeting of biting females to control mosquito-borne infectious diseases.Trends in parasitology · 2022Review
- Speciation and adaptation research meets genome editing.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Review
- Natural and Engineered Sex Ratio Distortion in Insects.Frontiers in ecology and evolution · 2022Article
- Genetically engineered insects with sex-selection and genetic incompatibility enable population suppression.eLife · 2022Article
- HUGE pipeline to measure temporal genetic variation inFrontiers in insect science · 2022Article
- Modeling-informed Engineered Genetic Incompatibility strategies to overcome resistance in the invasiveFrontiers in insect science · 2022Article
- Combating mosquito-borne diseases using genetic control technologies.Nature communications · 2021Review
- Adequacy and sufficiency evaluation of existing EFSA guidelines for the molecular characterisation, environmental risk assessment and post-market environmental monitoring of genetically modified insects containing engineered gene drives.EFSA journal. European Food Safety Authority · 2020Article
- Engineering multiple species-like genetic incompatibilities in insects.Nature communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Engineered reproductive species barriers are useful for impeding gene flow and driving desirable genes into wild populations in a reversible threshold-dependent manner. However, methods to generate synthetic barriers are lacking in advanced eukaryotes. Here, to overcome this challenge, we engineer SPECIES (Synthetic Postzygotic barriers Exploiting CRISPR-based Incompatibilities for Engineering Species), an engineered genetic incompatibility approach, to generate postzygotic reproductive barriers. Using this approach, we create multiple reproductively isolated SPECIES and demonstrate their reproductive isolation and threshold-dependent gene drive capabilities in D. melanogaster. Given the near-universal functionality of CRISPR tools, this approach should be portable to many species, including insect disease vectors in which confinable gene drives could be of great practical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.